CCR4 and T-cell non-Hodgkin lymphoma: Based on this finding, Perera et al. [35] developed CAR-T cells targeting CCR4 by specifically depleting Th2 and Tregs while preserving CD8 + and Th1 T cells, reporting significant antitumor effects and long-term remission potential in a mouse model of T-cell lymphoma.